Received: 18 June 2020
Accepted: 26 August 2020
First Online: 13 October 2020
: <i>Conflicts of interest & disclosures:</i> LTM has consultancy agreements with Eli Lilly, Astra Zeneca, Novartis, and Takeda; is a National (UK) Coordinator for the TOMMORROW, Amaranth and Generation I&II Clinical Trials, and the Janssen Chariot PRO studies; has received research funding for his Imperial team from Jannsen, Takeda, AstraZeneca, Novartis and UCB Pharmaceuticals; and does not hold any agreement with any of the funders in relation to patents, products in development relevant to this study, or marketed products. LN, BZ, GC & CdJ do not have any conflicts of interest nor disclosures to declare.
: <i>Declaration of Ethical Standards:</i> The authors confirm that this research complies with the current laws of the country in which they were performed.